CTLA4 and neoplasm: Superior tumor regression was obtained by combining VEE-TRP-2 administration with antagonist anti-CTL antigen-4 (CTLA-4) or agonist anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibodies (mAbs) [30].